Not Yet RecruitingNot Applicable

REal World MAIA UK OutcomEs

United Kingdom300 participantsStarted 2026-07

Plain-language summary

This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Diagnosis of NDMM * Not eligible for autologous stem cell transplant at diagnosis * Received frontline DRd treatment following NICE approval (post-September 2023) * Minimum 3 months of follow-up data available Exclusion Criteria: * Participation in an interventional clinical trial for first-line therapy * Insufficient treatment or follow-up data for analysis * DRd used in relapsed/refractory setting rather than newly diagnosed disease

What they're measuring

Overall response rate (OOR) at 12 months

Timeframe: 12 months

Real-world dosing strategy for DRd - starting doses of Daratumumab, Lenalidomide and dexamethasone in cycle 1 and relative dose intensity at 12 months

Timeframe: 12 months

Trial details

NCT IDNCT07532473

SponsorThe Royal Wolverhampton Hospitals NHS Trust

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2028-07

Contact for this trial

Tanweer Ahmed

01902 695065 rwh-tr.ukchart@nhs.net

View on ClinicalTrials.gov More Myeloma trials